

## Scientific program

**Thursday, February 16, 2006**

	<b>Opening Ceremony and Session 1</b>	
	Chair: <i>Heinz Ludwig (Vienna/Austria)</i> • <i>Hans-Jörg Senn (St. Gallen/Switzerland)</i>	
08.30	<b>Welcome addresses</b> <i>H.J. Senn (St. Gallen/CH) for Local Organizers</i> • <i>J. Cuzick (London/UK) for ISCaP</i> • <i>A. Costa (Milano/IT) for ESO</i> • <i>H. Ludwig (Vienna/AT) for ESMO</i> • <i>J. Janssens (Belgium) for ECP</i>	
09.00	<b>Opening Lectures</b>	
	Why We are in Danger to Lose the “War on Cancer” – <i>Clifton Leaf (Fortune Magazine, New York, NY/USA)</i>	<b>S1</b>
09.30	A Favorable View: Progress in Cancer Prevention – <i>Peter Greenwald (Bethesda, MD/USA)</i>	<b>S2</b>
10.00	<b>Coffee Break, Posters, Exhibition</b>	
	<b>Session 2: Genetic and Biologic Predispositions and Cancer Prevention: Defining Risk Groups and Beyond</b>	
	Chair: <i>Judy Garber (Boston, MA/USA)</i> • <i>Helmut Bartsch (Heidelberg/Germany)</i>	
10.30	Genetic Risk Assessment and Beyond: Anything New? – <i>Judy Garber (Boston, MA/USA)</i>	<b>S3</b>
10.50	Cancer Molecular Targeting: Can the Medicine of Today Become the Magic of Tomorrow – <i>Tak W. Mak (Toronto/Canada)</i>	<b>S4</b>
11.20	Genetic Prediction of Lung Cancer – <i>Jürgen Wolf (Cologne/Germany)</i>	<b>S5</b>
11.35	Genetic Risk Profiles for Cancer Susceptibility and Therapy Response – <i>Helmut Bartsch</i>	<b>S6</b>
11.45	Discussion	
12.00	<b>Keynote Lecture 1: Nanotechnology and Cancer Prevention</b> <i>Anna D. Barker (Bethesda, MD/USA)</i>	<b>S7</b>
12.30	<b>Lunch, Posters, Exhibition</b>	
	<b>Session 3: Preclinical Models and their Relevance for Clinical Cancer Prevention</b>	
	Chair: <i>Andreas J. Gescher (Leicester/UK)</i> • <i>Michael Pollak (Montreal/Canada)</i>	
14.00	What is the Relevance of In Vitro-Studies for Human Cancer Prevention? – <i>Reuben Lotan (Houston, TX/USA)</i>	<b>S8</b>
14.20	Applications of Genetically-Engineered Mice for Cancer Prevention Studies – <i>Jeffrey E. Green (Bethesda, MD/USA)</i>	<b>S9</b>
14.40	Tumor Promotion: A Target of Cancer Chemoprevention – <i>Friedrich Marks (Germany)</i>	<b>S10</b>
15.00	Short presentation (from submitted abstract) – <i>Gabriela Balogh (Philadelphia, PA/USA)</i>	<b>P7</b>
15.15	Discussion	
15.30	<b>Coffee, Posters, Exhibition</b>	
	<b>Session 4: Prospects of Surrogate Endpoints and Biomarkers in Cancer Prevention</b>	
	Chair: <i>Frank F. Meyskens (Irvine, CA/USA)</i> • <i>Friedrich Marks (Heidelberg/Germany)</i>	
16.00	IGF-Related Signalling and Cancer Development – <i>Michael Pollak (Montreal/Canada)</i>	<b>S11</b>
16.20	Do Surrogate Marker Results Transform to Clinical Prevention Success? – <i>J. Jack Lee (Houston, TX/USA)</i>	<b>S12</b>
16.40	Challenges in Evaluating Molecular Markers as Surrogates for Cancer Prevention – <i>David F. Ransohoff (Chapel Hill, NC/USA)</i>	<b>S13</b>
17.00	Short presentation (from submitted abstract) – <i>Jianwei Zhou (Nanjing/China)</i>	<b>P9</b>
17.15	Discussion	
17.30	<b>Adjourn</b> Welcome Apéro-Reception for all, with Appenzell Music (University Foyer)	
19.30	Faculty dinner (Restaurant Schlössli am Spisertor)	

**Friday, February 17, 2006**

<b>Session 5: Prevention of Female and Male Genital Cancers</b>		
Chair: <i>Roland Richter (St. Gallen/Switzerland)</i> • <i>Irma Russo (Philadelphia, PA/USA)</i>		
08.30	Cervical Cancer: HPV-Screening and Vaccination – <i>Bradley Monk (Orange, CA/USA)</i>	<b>S14</b>
08.50	Ovarian Cancer Prevention + Early Detection: Mission Impossible? – <i>Robert Bast (Houston, TX/USA)</i>	<b>S15</b>
09.10	Prevention of Prostate Cancer: More Questions than Data! – <i>H.P. Schmid (St. Gallen/Switzerland)</i>	<b>S16</b>
09.30	Primary Prevention of Breast Cancer by Hormone-Induced Differentiation – <i>Irma H. Russo (Philadelphia, PA/USA)</i>	<b>S17</b>
09.45	Discussion	
<hr/>		
10.00	<b>Coffee, Posters, Exhibition</b>	
<hr/>		
<b>Session 6: Inflammation, Infection and Cancer Prevention</b>		
Chair: <i>Hoyoku Nishino (Kyoto/Japan)</i> • <i>Magnus von Knebel Doeberitz (Heidelberg/Germany)</i>		
10.30	Basic Mechanisms of Prevention of Inflammation-Induced Cancers – <i>Stefan Rose-John (Kiel/Germany)</i>	<b>S18</b>
10.50	Prevention of Viral-Induced Hepatomas: Antioxidant Trials in Japan – <i>Hoyoku Nishino (Kyoto/Japan)</i>	<b>S19</b>
11.10	Epstein-Barr-Virus-Associated Tumours, Pathogenesis and Perspectives on Prevention – <i>Henri-Jacques Delecluse (Heidelberg/Germany)</i>	<b>S20</b>
11.30	Perspectives in Prevention of HPV-Induced Cervical Cancer – <i>Magnus von Knebel Doeberitz (Heidelberg/Germany)</i>	<b>S21</b>
11.45	Discussion	
<hr/>		
12.00	<b>Keynote Lecture 2: Cox-2-Cancer Chemoprevention: Picking up the Pieces</b> <i>Monica Bertagnolli (Boston, MA/USA)</i>	<b>S22</b>
<hr/>		
12.30	<b>Lunch, Posters, Exhibition</b>	
12.30–13.15	ISCaP General Assembly (Audi Max)	
<hr/>		
<b>Session 7: Prevention of Skin and Brain Tumors</b>		
Chair: <i>Frank L. Meyskens (Irvine, CA/USA)</i> • <i>Paul Kleihues (Berlin/Germany)</i>		
14.00	New Perspectives on Melanoma Pathogenesis and Chemoprevention – <i>Frank L. Meyskens (Irvine, CA/USA)</i>	<b>S23</b>
14.20	Emerging Issues in Skin Cancer Control – <i>Craig Sinclair (Carlton, Vic./Australia)</i>	<b>S24</b>
14.40	Are Gliomas Preventable? – <i>Victor A. Levin (Houston, TX/USA)</i>	<b>S25</b>
15.00	Short presentation (from submitted abstract) – <i>Albena Dinkova-Kostova (Baltimore, MD/USA)</i>	<b>P38</b>
15.15	Discussion	
<hr/>		
15.30	<b>Coffee, Posters, Exhibition</b>	
<hr/>		
<b>Session 8: Prevention of Colorectal and Renal Cancers</b>		
Chair: <i>Thomas Cerny (St. Gallen/Switzerland)</i> • <i>Gad Rennert (Haifa/Israel)</i>		
16.00	Primary Dietary Prevention: Is the Fiber Story Over? – <i>Cheryl L. Rock (San Diego, CA/USA)</i>	<b>S26</b>
16.20	Cancer Prevention in the Different Genetic Risk Groups for Colorectal Cancer – <i>Hansjakob Müller (Basel/Switzerland)</i>	<b>S27</b>
16.40	Progress in Prevention and Early Detection of Colorectal Cancer – <i>Gad Rennert (Haifa/Israel)</i>	<b>S28</b>
17.00	Short presentation (from submitted abstract) – <i>Clarissa Gerhäuser (Heidelberg/Germany)</i>	<b>P35</b>
17.15	Discussion	
<hr/>		
17.30	<b>Adjourn</b>	
<hr/>		
19.30	<b>Musical Dinner Reception</b> (for all), Pfälzkeller	

## Saturday, February 18, 2006

<b>Session 9: Prevention of Breast Cancer</b>		
Chair: <i>Jack Cuzick (London/UK)</i> • <i>M. Osborne (New York, NY/USA)</i>		
08.30	A New Paradigm in Breast Cancer Prevention – <i>José H. Russo (Philadelphia, PA/USA)</i>	<b>S29</b>
08.50	The Importance of Estrogen Withdrawal in Breast Cancer Prevention – <i>Anthony Howell (Manchester/UK)</i>	<b>S30</b>
09.10	Multiple Outcome Prevention Trials Using SERMS – <i>Trevor Powles (London/UK)</i>	<b>S31</b>
09.30	Gene Expression Profiles Associated with HRT and Its Influence on Breast Cancer Risk – <i>Per Hall (Stockholm/Sweden)</i>	<b>S32</b>
09.45	Discussion	
10.00	<b>Coffee, Exhibition</b>	
<b>Session 10: The Future of Cancer (Chemo)Prevention</b>		
Chair: <i>Peter Boyle (Lyon/France)</i> • <i>Peter Greenwald (Bethesda, MD/USA)</i>		
10.30	Angiogenesis & Cancer Prevention: A Vision – <i>Adriana Albini (Genova/Italy)</i>	<b>S33</b>
10.50	Ultraviolet-B Irradiance, Vitamin D and Human Cancer: A Vision for the Future – <i>William Grant (San Francisco, CA/USA)</i>	<b>S34</b>
11.10	Uncovering Novel Targets for Cancer Chemoprevention – <i>Ethan Dmitrovsky (Hanover, NH/USA)</i>	<b>S35</b>
11.30	Short presentation (from submitted abstract) – <i>Vikas Khurana (Shreveport, LA/USA)</i>	<b>P36</b>
11.45	Discussion	
12.00	<b>Closing Keynote Lecture 3: Balancing Risk and Benefit in Cancer Prevention</b> <i>Peter Boyle (Lyon/France)</i>	<b>S36</b>
12.30	<b>Closing Remarks</b>	
12.35	<b>Adjourn</b>	

This conference counts for 15 ESMO-MORA credit points.